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Abstract: Persistent pulmonary hypertension of the newborn (PPHN) is a syndrome of failed
circulatory adaptation at birth due to delay or impairment in the normal fall in pulmonary vascular
resistance (PVR) that occurs following birth. The fetus is in a state of physiological pulmonary
hypertension. In utero, the fetus receives oxygenated blood from the placenta through the umbilical
vein. At birth, following initiation of respiration, there is a sudden precipitous fall in the PVR and an
increase of systemic vascular resistance (SVR) due to the removal of the placenta from circulation.
There is dramatic increase in pulmonary blood flow with a decrease in, and later reversal of shunts
at the foramen ovale and ductus arteriosus. The failure of this normal physiological pulmonary
transition leads to the syndrome of PPHN. PPHN presents with varying degrees of hypoxemic
respiratory failure. Survival of infants with PPHN has significantly improved with the use of gentle
ventilation, surfactant and inhaled nitric oxide (iNO). PPHN is associated with significant mortality
and morbidity among survivors. Newer agents that target different enzymatic pathways in the
vascular smooth muscle are in different stages of development and testing. Further research using
these agents is likely to further reduce morbidity and mortality associated with PPHN.
Keywords: oxygen; hypoxemia; nitric oxide; pulmonary blood flow
1. Introduction
During fetal life, pulmonary vascular resistance (PVR) is high and pulmonary blood flow (Qp)
is low [1]. Following a normal transition, PVR decreases and Qp increases at birth [2]. Persistent
pulmonary hypertension of the newborn (PPHN) is a syndrome of failed circulatory adaptation due to
the delay or impairment of the normal fall in PVR that occurs following birth [3]. PPHN is associated
with significant mortality and morbidity among survivors. The incidence of PPHN is 1.8 to 2 per
1000 births [4,5] and about 2% in premature infants with respiratory distress syndrome (RDS).
2. Pathophysiology of Persistent Pulmonary Hypertension
The fetus is in a state of physiological pulmonary hypertension (PH) [6]. In utero, the fetus
receives oxygenated blood from the placenta through the umbilical vein. Oxygenated umbilical venous
blood enters the right atrium and is diverted to the left atrium through the foramen ovale. During
fetal life, in most mammalian species, the organ of gas exchange (placenta) receives approximately
30–45% of combined ventricular cardiac output [7]. The lungs receive between 8 to 21% [8] of the
combined ventricular output through the pulmonary arteries [7]. The pressure gradient drives the
flow of blood in the fetal cardiovascular system away from the high resistance low flow pulmonary
circulation, towards the low resistance high flow systemic and placental circulation, leading to right to
left shunting through the ductus arteriosus into the descending aorta. The high PVR in the fetus is
maintained by a combination of anatomical, physical, biochemical and humoral factors. Compression
of pulmonary blood vessels by the fluid-filled alveoli, lack of rhythmic distension of the lungs and
narrowing of the vascular lumen by the cuboidal configuration of the endothelial cells all play a role in
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maintaining the elevated PVR in the fetus. Hypoxic pulmonary vasoconstriction is maintained due to
the low resting arteriolar and alveolar oxygen tension. Humoral mediators such as endothelin-1, and
arachidonic acid metabolites such as leukotrienes and thromboxane and lack of vasodilators such as
nitric oxide (NO) and prostacyclin (PGI2) contribute to high PVR [2,9]. The low placental systemic
vascular resistance in the fetus is maintained by high levels of estrogen, prostaglandins, and NO
produced by the placenta.
At birth, following initiation of respiration (increasing alveolar oxygen tension and ventilation)
there is a sudden, precipitous fall in the PVR and an increase in SVR due to the removal of the
placenta from circulation. Pulmonary endothelial NO acting via the cyclic guanosine monophosphate
(cGMP) pathway and PGI2 through the cyclic adenosine monophosphate (cAMP) pathway mediate
pulmonary vasodilation following birth. There is an eight-fold increase in Qp with a decrease in,
and later reversal of shunts at the foramen ovale and ductus arteriosus. The failure of this normal
physiological pulmonary transition leads to the syndrome of PPHN often manifesting as hypoxic
respiratory failure (HRF).
3. Etiology of Persistent Pulmonary Hypertension of the Newborn
Based on etiology, PPHN can be categorized into seven broad groups (Figure 1):
1. Idiopathic—No lung disease is present and Qp is decreased due to abnormal vascular remodeling
leading to pulmonary vasoconstriction.
2. Abnormal transition at birth—perinatal asphyxia, RDS, and transient tachypnea of newborn,
(TTN) resulting in impaired pulmonary vasodilation at birth.
3. Parenchymal disorders (also known as “secondary PPHN”)—such as due to meconium aspiration
syndrome (MAS) and pneumonia.
4. Abnormal lung development—pulmonary hypoplasia due to oligohydramnios secondary to
renal dysfunction/anomalies or prolonged rupture of membranes, or congenital diaphragmatic
hernia (CDH) and other pulmonary malformations.
5. Intravascular obstruction due to hyperviscosity—polycythemia.
6. Pulmonary hypertension (PH) in preterm infants in the initial phase of RDS [10].
7. Pulmonary venous hypertension [11].
3.1. Idiopathic PPHN
Idiopathic PPHN is caused by impaired pulmonary vascular relaxation that occurs following birth
in the absence of parenchymal lung disease. Histopathological changes include increased vascular
smooth muscle proliferation in the pulmonary blood vessels that extend into intra acinar arteries. One
of the mechanisms of idiopathic PPHN is due to premature closure of the ductus arteriosus in utero,
which forces blood through the constricted pulmonary vasculature leading to increased sheer stress
and remodeling. Nonsteroidal anti-inflammatory drugs (NSAIDs) [12] and selective serotonin reuptake
inhibitors (SSRIs) taken during pregnancy [13] have been associated with PPHN in the offspring but
more recent studies have reported conflicting results [14]. Decreased endogenous NO synthesis (as can
be associated with urea cycle enzyme defects) [15], bioavailability of NO, and vascular responsiveness
to vasodilators may play a role in the etiopathogenesis of this condition. This condition is also called
black lung PPHN due to the characteristic appearance on chest X-ray due to lack of lung disease and
decreased pulmonary vascularity.
3.2. Abnormal Pulmonary Transition
Abnormal pulmonary transition at birth, due to for example perinatal asphyxia can lead to
hypoxemia, hypercarbia and metabolic acidosis, all of which cause pulmonary vasoconstriction and
increased intra- and extra-pulmonary shunting. Decreased alveolar recruitment and lung volume can
cause physical constriction of the intrapulmonary blood vessels further impeding pulmonary blood
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flow. Optimizing lung recruitment to functional residual capacity (FRC) and effective ventilation often
lead to reversal of the pathophysiological process associated with these conditions. Preterm infants
with severe RDS and infants born by cesarean section without labor experience a slower decrease in
PVR compared to term infants born by vaginal delivery.
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and pulmonary vascular development. In addition, CDH is often associated with abnormalities of 
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frequently complicate the clinical course in infants with CDH [16,17]. 
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Extremely premature infants are at risk of PH/HRF in the first few days of postnatal life. The 
fetal PVR is high during the canalicular stage secondary to paucity of pulmonary vascular network 
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3.5. Prematurity
Extremely premature infants are at risk of PH/HRF in the first few days of postnatal life. The fetal
PVR is high during the canalicular stage secondary to paucity of pulmonary vascular network
reducing the cross sectional area of the immature pulmonary vascular bed. Pulmonary vasculature at
mid-gestation is less responsive to oxygen mediated pulmonary vasodilation. These infants typically
respond poorly to inhaled pulmonary vasodilators such as iNO [18]. However, there is a subset of
preterm infants with prolonged rupture of membranes, and oligohydramnios with typical term-PPHN
physiology who may have a better response to iNO [19].
3.6. Pulmonary Venous Hypertension
These conditions present with HRF and can be clinically indistinguishable from pulmonary
arterial hypertension [20]. The chest X-ray appearance shows increased pulmonary vascularity and
fluid congestion. The decrease in pulmonary blood flow is due to backpressure from impaired venous
drainage into the left atrium (Figure 1). Left-sided obstructive congenital heart disease (mitral atresia,
hypoplastic left heart syndrome, critical coarctation of aorta), total anomalous pulmonary venous
connection with obstruction [21], pulmonary vein stenosis can all present with varying degrees of
pulmonary venous hypertension. Left ventricular dysfunction due to asphyxia, sepsis or CDH can
also present with pulmonary venous hypertension. The diagnosis is made on echocardiography
by evaluating the direction of fetal shunts. Inhaled NO is contraindicated in these conditions as it
increases pulmonary edema and causes deterioration of gas exchange [22].
4. Clinical Presentation
PPHN presents with varying degrees of HRF. (For the differential diagnosis of hypoxemia in
neonates—see Table 1) The characteristic findings of PPHN are labile hypoxemia and pre—post
ductal saturation gradient (manifested clinically as differential cyanosis). Infants with PPHN have
wide swings in arterial oxygen saturation levels due to acute changes in pulmonary blood flow
and right-to-left shunt associated with episodic changes in PVR in response to minimal stimulation.
A pre to post ductal gradient of greater than 10% is common in infants with PPHN [23] Physical
examination findings are often minimal with a loud second heart sound and systolic murmur of
tricuspid regurgitation. A chest X-ray is often helpful to diagnose the underlying cause and to assess
response to changes with ventilator therapy.
Table 1. Differential diagnosis of hypoxemia in newborn infants.
Lung Disease without PPHN Cyanotic Congenital Heart Disease PPHN
History Fetal distress, PROM,chorioamnionitis Antenatal diagnosis
Often negative other than in
secondary PPHN
Respiratory distress Present Usually absent Often present
Oxygen saturation on
pulse oximetry
Improves with supplemental
oxygen
Fixed low saturations Minimal
response to supplemental oxygen
Labile saturations.
Differential cyanosis
Hyperoxia test * PaO2 often > 150 mm Hg PaO2 often < 100 mm Hg PaO2 often > 100 mm Hg
PaCO2 Elevated Normal/low
Often elevated (except in
idiopathic PPHN)
Hyperoxia-
Hyperventilation * PaO2 > 150 mm Hg PaO2 often < 100 mm Hg
PaO2 improves with
hyperventilation
Chest X ray Abnormal Abnormalities of cardiac silhouetteand pulmonary vascularity
Decreased vascularity in
idiopathic PPHN
Echocardiogram Normal Structural cardiac abnormalities
Structurally normal heart
(see text for characteristic echo
findings of PPHN)
* Both hyperoxia and hyperoxia hyperventilation tests are not used routinely in clinical practice due to increased
availability of echocardiography in most institutions. These tests expose the infant to hyperoxia and hypocarbia
with the potential to cause oxidative stress and decreased cerebral perfusion respectively.
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4.1. Echocardiography
Right ventricular hypertrophy, deviation of the interventricular septum to the left, tricuspid
regurgitation (TR) and right to left or bidirectional shunting at the patent foramen ovale (PFO) and
patent ductus arteriosus (PDA) are the cardinal echocardiographic findings in PPHN (Figure 2).
The right ventricular systolic pressure can be estimated using the modified Bernoulli equation as 4v2 +
right atrial pressure, where v = maximal velocity of the TR jet in m/s. Changes in pulmonary arterial
pressure, myocardial function and blood flow patterns across the ductus and foramen ovale can be
monitored over time by echocardiography. Echocardiograms can assess response to therapy in infants
with PPHN [24].
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volume with positive end expiratory pressure (PEEP) and providing adequate mean airway pressure 
and or surfactant should be attempted. 
Right-to-left shunt at both PDA and PFO is suggestive of increased PVR and extrapulmonary 
shunting and is likely due to PPHN. Inhaled pulmonary vasodilator therapy such as iNO should be 
the primary therapy after optimizing lung recruitment in these patients. 
Right-to-left shunt at the ductus arteriosus and left-to-right shunt at the PFO is suggestive of 
pulmonary hypertension with left ventricular dysfunction and is often seen in CDH, asphyxia and 
sepsis. In this setting, pulmonary vasodilator therapy alone may worsen oxygenation by causing 
increasing fluid congestion in the lungs. Pulmonary vasodilator therapy combined with inotropy 
with milrinone may be helpful in this situation by supporting left ventricular function. A similar 
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Figure 2. Echocardiographic findings in normal infants (left) and in PPHN (right). Soon after birth the
pressures within the left-sided chambers of the heart are higher than in the right and the fetal shunts are
reversed. The interatrial shunt and the shunt across the patent ductus arteriosus (PDA) is left to right.
In infants with PPHN the pressures remain elevated in the right atrium and ventricle with right to left
shunt at the atrial level and at the PDA causing desaturation (due to interatrial shunt) and differential
cyanosis (due to PDA). There is right ventricular hypertrophy with bulging of the interventricular
septum to the left and tricuspid regurgitation. SVR—Systemic vascular resistance, PVR—Pulmonary
vascular resistance. Copyright Satyan Lakshminrusimha.
The direction of blood flow across the fetal shunts PDA and PFO provide critical information
about the diagnosis and response to interventions in infants with HRF.
In infants with hypoxemia and left-to-right shunt at both PDA and PFO, the hypoxemia is due
to intrapulmonary shunting and interventions to improve lung recruitment such as optimizing lung
volume with positive end expiratory pressure (PEEP) and providing adequate mean airway pressure
and or surfactant should be attempted.
Right-to-left shunt at both PDA and PFO is suggestive of increased PVR and extrapulmonary
shunting and is likely due to PPHN. Inhaled pulmonary vasodilator therapy such as iNO should be
the primary therapy after optimizing lung recruitment in these patients.
Right-to-left shunt at the ductus arteriosus and left-to-right shunt at the PFO is suggestive of
pulmonary hypertension with left ventricular dysfunction and is often seen in CDH, asphyxia and
sepsis. In this setting, pulmonary vasodilator therapy alone may worsen oxygenation by causing
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increasing fluid congestion in the lungs. Pulmonary vasodilator therapy combined with inotropy with
milrinone may be helpful in this situation by supporting left ventricular function. A similar shunting
pattern is also seen in infants with pulmonary vein stenosis, and congenital heart disease with ductal
dependent systemic blood flow as in hypoplastic left heart syndrome, critical aortic stenosis, mitral
atresia, interrupted aortic arch, and critical coarctation of aorta.
Left-to-right shunt at the ductus arteriosus and right-to-left shunt at the foramen ovale is seen
in infants with cyanotic congenital heart disease with ductal dependent pulmonary blood flow such
as tricuspid atresia, critical pulmonary stenosis and pulmonary atresia. It is important to exclude
congenital heart disease prior to initiation of pulmonary vasodilator therapy in infants presenting
with HRF.
5. Assessment of Severity of HRF and Monitoring Response to Therapy
Objective assessment of oxygenation in infants with PPHN/HRF can be performed with one of
the following indices:
• Oxygenation index (OI) = FiO2 × mean airway pressure × 100/PaO2
Severity of HRF based on OI:
# Mild ≤15
# Moderate 15 to ≤25
# Severe 25 to ≤40 and
# Very severe >40
• Alveolar—arterial oxygen gradient (A-a gradient or A-aDO2). This estimates the partial pressure
gradient of oxygen from the alveolus to the aorta.
A-aDO2 = [FiO2 × (Barometric pressure − water vapor pressure) − PaCO2/R)] − PaO2.
# Where R is the respiratory quotient (R = 1, in an infant receiving exclusive intravenous
dextrose and approximately 0.8 when on mixed diet).
# The normal A-aDO2 is 4–20 mm of Hg. A-aDO2 can be above 600 mm Hg in very severe
cases of HRF. An online calculator is available at http://perinatology.com/calculators/A-
a%20gradient.htm.
• P/F ratio is the ratio of the partial pressure of oxygen (in mm Hg) in the arterial blood to the
fractional inspired oxygen concentration. P/F ratio = PaO2/ FiO2
Severity assessment based on P/F ratio:
# Mild >200 to ≤300.
# Moderate >100 to ≤200 and
# Severe ≤100 mm Hg.
• Note: For calculation of OI and P/F ratios, it is preferable to use preductal blood gases [25].
Preductal PaO2 accurately predicts oxygen delivery to vital organs such as the brain and heart
and is not altered by right to left shunting at the PDA. However, many patients with PPHN have
umbilical arterial access (postductal blood gases) resulting in lower PaO2 and higher OI and lower
P/F ratio compared to preductal evaluation.
• Oxygen saturation index (OSI)—All of the above indices require arterial blood gas for evaluation
and hence the need for arterial access. OSI is a noninvasive index of gas exchange and is calculated
as follows:
# OSI = Mean airway pressure × FiO2 × 100/Preductal SpO2.# OSI has been shown to correlate well in infants with HRF, OI ≈ 2 × OSI [26].
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6. Management
The goals of therapy in PPHN are to promote lung recruitment, pulmonary vasodilation, improve
oxygenation and provide adequate oxygen delivery to the tissues while minimizing oxidative stress
and free radical injury.
6.1. Supportive Therapies
Maintaining normal body temperature, glucose level, ionic calcium and sedation/ analgesia are
important for optimal outcomes in patients with PPHN.
6.2. Lung Recruitment
A common cause of failure to respond to treatment in HRF with impaired oxygenation and
ventilation is inadequate lung recruitment. Optimizing lung recruitment with the use of PEEP to
achieve lung expansion to functional residual capacity (FRC) approximately 8–9 ribs expansion on
anteroposterior chest X-ray) often ensures adequate lung recruitment. Underinflation and overinflation
increase PVR due to the mechanical effects on the extra-alveolar and intra-alveolar pulmonary blood
vessels. Atelectasis increases intrapulmonary right to left shunting leading to worsening hypoxia and
hypercarbia. Overinflation can impede venous return and cause systemic hypotension.
6.3. Oxygenation
Oxygen is a potent vasodilator and hypoxia causes pulmonary vasoconstriction. Supplemental
oxygen should be provided to achieve normoxia (PaO2 between 50 and 80 mmHg) [27]. Hyperoxia
(PaO2 > 100 mmHg) does not enhance pulmonary vasodilation [28,29] and increases the formation
of oxygen free radicals that increases pulmonary arterial contractility [30,31] and impairs vasodilator
response to iNO. The optimal saturation target range for patients with PPHN is not known. Targeting
a lower limit of preductal SpO2 of 92% provides a buffer to hypoxic pulmonary vasoconstriction and
an upper limit of 97% ensures the optimal balance of pulmonary vasodilation and minimizes adverse
effects from oxidative stress [32,33]. Adequacy of tissue oxygen delivery should be followed closely
by pulse oximetry and blood gas monitoring for acidosis. Near infrared spectroscopy (NIRS) is a
non-invasive assessment of oxygen delivery and is commonly used in postoperative management of
congenital heart disease. Although not routinely used in the management of PPHN, there may be
benefit to the use of NIRS in the presence of PPHN associated with hypoxic ischemic encephalopathy.
6.4. Surfactant Replacement Therapy
Surfactant inactivation occurs with MAS, pneumonia and sepsis. Surfactant therapy leads to
improvement in oxygenation by improving V/Q matching and decreases intrapulmonary shunting.
In newborn infants with parenchymal lung disease, surfactant replacement prior to initiation of iNO
improves outcome and reduces the need for extracorporeal membrane oxygenation (ECMO) [34].
6.5. Inhaled Nitric Oxide (iNO)
Inhaled nitric oxide remains the only United States Food and Drug Administration
(FDA)-approved pulmonary vasodilator for infants with PPHN. Nitric oxide is produced by
the endothelial cells and causes pulmonary vasodilation through generation of cyclic guanosine
monophosphate (cGMP) (Figure 3). Inhaled NO causes selective vasodilation of the pulmonary
circulation as it diffuses from the alveolus into the smooth muscle cells and causes pulmonary
vasodilation [35]. Inhaled NO is inactivated by hemoglobin in the circulation and hence has minimal
systemic vasodilator effect. Inhaled NO causes vasodilation of pulmonary blood vessels that are
adjacent to well-ventilated alveoli and decreases intrapulmonary right-to-left shunting and improves
V/Q matching (microselective effect).
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Inhaled NO is usually initiated when the oxygenation index reaches 15–25. Delay in initiation of
pulmonary vasodilator therapy has been shown to be associated with worsening of HRF. The starting
dose of iNO is usually 20 ppm. Higher doses do not enhance pulmonary vasodilation and may increase
the incidence of side effects. Clinical response is defined as an improvement in PaO2 by at least 20 mm
Hg following initiation of iNO. In infants who fail to respond to iNO after optimizing lung recruitment,
ventilation and hemodynamic support, it is important to discontinue iNO to prevent downregulation of
endogenous NO pathway [36] and prevent injury by formation of peroxynitrite [32]. Once oxygenation
response is achieved, iNO dose can be weaned in decrements of 5 ppm till 5 ppm is reached and
by 1 ppm subsequently (see weaning protocol) [37]. It is important to monitor methemoglobin and
nitrogen dioxide levels at initiation and daily during treatment with iNO. The approach to weaning
iNO used in our center is shown in Figure 4.
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Figure 3. Pulmonary vasodilators—Endothelium-derived vasodilators: prostacyclin (PGI2), nitric oxide
(NO), and vasoconstrictor (endothelin, ET-1). The enzymes, cyclooxygenase (COX) and prostacyclin
synthase (PGIS) are involved in the synthesis of prostacyclin. Prostacyclin through (PGI2 receptor (IP)
stimulates adenylate cyclase (AC) to produce cAMP. cAMP is broken down by phosphodiesterase 3A
(PDE3A) in the smooth muscle cell. Milrinone inhibits PDE 3A and increases cAMP levels in pulmonary
arterial smooth muscle cells and cardiac myocytes resulting in vasodilation and inotropy. Endothelin
is a powerful vasoconstrictor and acts on ET-A receptors in the smooth muscle cell and increases
ionic calcium concentration. A second endothelin receptor (ET-B) on the endothelial cell stimulates
NO release and vasodilation. Endothelial nitric oxide synthase (eNOS) catalyzes the production of
NO which diffuses from the endothelium to the smooth muscle cell and stimulates soluble guanylate
cyclase (sGC) enzyme to produce cyclic guanosine monophosphate (cGMP). cGMP is broken down by
the PDE5 enzyme in the smooth muscle cell. Sildenafil inhibits PDE5 and increases cGMP levels in
pulmonary arterial smooth muscle cells. cAMP and cGMP reduce cytosolic ionic calcium concentrations
and induce smooth muscle relaxation and pulmonary vasodilation. NO is a free radical and avidly
combines with superoxide anions to form a toxic vasoconstrictor, peroxynitrite. The bioavailability of
NO in a tissue is determined by the local concentration of superoxide anions. Hyperoxic ventilation
can increase the risk of formation of superoxide anions in the pulmonary arterial smooth muscle cells
and limit the bioavailability of NO. Copyright Satyan Lakshminrusimha.
Children 2017, 4, 63 9 of 14
Children 2017, 4, 63  9 of 14 
 
 
Figure 4. Guidelines for initiation and weaning iNO in PPHN/hypoxic respiratory failure (HRF) in 
Neonatal Intensive Care Unit (NICU )(adapted from the protocol at Women & Children’s Hospital of 
Buffalo). The recommended starting dose of iNO is 20 parts per million (ppm). Improvement in  
PaO2 ≥ 20 mm Hg or hemoglobin saturation by pulse oximetry ≥ 5% is considered complete response. 
In patients who fail to respond iNO, measures needed to optimize of lung recruitment and 
hemodynamics need to be undertaken. iNO should be discontinued if there no response.  
In responders wean FiO2 initially while maintaining PaO2 between 60 and 80 mm Hg. Once PaO2 is 
stable and FiO2 is below 0.6, start weaning iNO by 5 ppm every 4 h till 5 ppm. Below 5 ppm wean 
iNO by 1 ppm every 4 h. During weaning >5% drop in pulse oximetry or sustained increase in  
FiO2 > 0.15 to maintain PaO2 > 60 mm Hg is considered weaning failure, and previous dose of iNO 
should be resumed. Weaning should be resumed once stable. Monitor methemoglobin levels at 
baseline, 2 and 8 h following initiation and every 48 h thereafter [37]. PEEP—Positive End Expiratory 
Pressure, MAP—Mean Airway Pressure, ECMO—Extracorporeal Membrane Oxygenation. 
Copyright Satyan Lakshminrusimha. 
6.6. Prostaglandins 
Prostacyclins are the mainstay of therapy for pulmonary hypertension in adults. Evidence for 
use in newborns with PPHN is limited to case series. Prostaglandins cause activation of adenylate 
cyclase increasing the cAMP levels in the vascular smooth muscle cells leading to pulmonary 
vasodilation (Figure 3) [38]. Intravenous prostacyclins can lead to systemic hypotension and 
worsening of VQ mismatch. Inhaled PGI2 by nebulization has been shown to be effective in infants 
who had poor response to iNO [39]. 
6.7. Phosphodiesterase Inhibitors 
Cyclic mononucleotides cGMP and cAMP are degraded by phosphodiesterase (PDE) enzymes 
in the pulmonary artery smooth muscle cells. Milrinone is a PDE3A inhibitor and enhances cAMP 
Figure 4. Guidelines for initiation and weaning iNO in PPHN/hypoxic respiratory failure (HRF) in
Neonatal Intensive Care Unit (NICU) (adapted from the protocol at Women & Children’s Hospital of
Buffalo). The recommended starting dose of iNO is 20 parts per million (ppm). Improvement in PaO2
≥ 20 mm Hg or hemoglobin saturation by pulse oximetry ≥ 5% is considered complete response. In
patients who fail to respond iNO, measures needed to optimize of lung recruitment and hemodynamics
need to be undertaken. iNO should be discontinued if there no response. In responders wean FiO2
initially while maintaining PaO2 between 60 and 80 mm Hg. Once PaO2 is stable and FiO2 is below 0.6,
start weaning iNO by 5 ppm every 4 h till 5 ppm. Below 5 ppm wean iNO by 1 ppm every 4 h. During
weaning >5% drop in pulse oximetry or sustained increase in FiO2 > 0.15 to maintain PaO2 > 60 mm
Hg is considered weaning failure, and previous dose of iNO should be resumed. Weaning should be
resumed once stable. Monitor methemoglobin levels at baseline, 2 and 8 h following initiation and
every 48 h thereafter [37]. PEEP—Positive End Expiratory Pressure, MAP Mean Airway Pressure,
ECMO—Extracorporeal Membrane Oxygenation. Copyright Satyan Lakshminrusimha.
6.6. Prostaglandins
Prostacyclins are the mainstay of therapy for pulmonary hypertension in adults. Evidence for use
in newborns with PPHN is limited to case series. Prostaglandins cause activation of adenylate cyclase
increasing the cAMP levels in the vascular smooth muscle cells leading to pulmonary vasodilation
(Figure 3) [38]. Intravenous prostacyclins can lead to systemic hypotension and worsening of VQ
mismatch. Inhaled PGI2 by nebulization has been shown to be effective in infants who had poor
response to iNO [39].
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6.7. Phosphodiesterase Inhibitors
Cyclic mononucleotides cGMP and cAMP are degraded by phosphodiesterase (PDE) enzymes
in the pulmonary artery smooth muscle cells. Milrinone is a PDE3A inhibitor and enhances cAMP
levels in the arterial smooth muscle cells and cardiac myocytes resulting in vasodilation and inotropy
(Figure 3). Milrinone is administered as a loading dose of 50 µg/kg/min given over 30 min followed
by 0.33 µg/kg/min as a continuous infusion. The dose may be titrated up to 1 µg/kg/min with close
monitoring of systemic blood pressure.
Sildenafil is a PDE5 inhibitor, which decreases breakdown of cGMP resulting in pulmonary
vasodilation (Figure 3) [40]. Sildenafil may be used in combination with iNO, or may be used alone
to prevent rebound PH following withdrawal of iNO. Hyperoxic ventilation increases PDE5 [41],
and PDE5 inhibitors may be particularly effective in patients who have been exposed to hyperoxic
ventilation. The typical dose of intravenous sildenafil is a loading dose of 0.42 mg/kg over 3 h followed
by 0.07 mg/kg/h [42]. The starting dose of oral sildenafil is 0.5 mg/kg/dose every eight h and can be
increased to a maximum of 3–8 mg/kg/day, divided every 6–8 h. Phosphodiesterase inhibitors dilate
the pulmonary vasculature irrespective of ventilation status and could cause V/Q mismatch leading
to worsening oxygenation. Systemic vasodilation and hypotension are particularly common during
initiation of therapy, hence intravascular volume status should be optimized, and blood pressure
monitored closely during treatment with phosphodiesterase inhibitors.
6.8. Inotropes
Systemic hypotension due to low systemic vascular resistance or left ventricular dysfunction is
common in infants with PPHN. Right ventricular dysfunction and failure occurs due to increased
afterload in infants with severe PPHN. Optimizing cardiac output with adequate volume expansion
and inotropic support is important for achieving optimal gas exchange and systemic oxygen delivery.
(1) In the presence of systemic hypotension without cardiac dysfunction, the agents of choice are
dopamine, norepinephrine and vasopressin (pressor support).
(2) When systemic hypotension is associated with cardiac dysfunction, epinephrine or a combination
of dopamine/vasopressin and milrinone are the agents of choice.
(3) In the presence of stable systemic blood pressure and cardiac dysfunction, milrinone is the agent
of choice.
(4) Studies in the lamb model of PPHN have shown increase in pulmonary arterial pressure and
decreased pulmonary blood flow following initiation of dopamine. In control lambs with
normal pulmonary vasculature, dopamine increases the systemic blood pressure with relatively
small increase in pulmonary arterial pressure. In contrast, lambs with remodeled pulmonary
vasculature and PPHN induced by antenatal ductal ligation, dopamine, especially at doses
>10 µg/kg/min, results in a greater increase in pulmonary arterial pressure [9].
(5) The use of dobutamine is often associated with a fall in systemic blood pressure resulting in
exacerbation of right to left shunting and systemic desaturation. Dobutamine causes increase in
myocardial oxygen requirement which may worsen myocardial dysfunction in PPHN.
Maintaining adequate (physiological) systemic blood pressure decreases systemic oxygen
desaturation by decreasing the pulmonary to systemic shunt through the ductus arteriosus. It is
a common practice to increase systemic blood pressure to supraphysiological levels above pulmonary
arterial pressures to prevent right-to-left shunting and desaturation [43]. Iatrogenic systemic
hypertension does not improve oxygen delivery to the brain or myocardium (preductal), but may
increase stress on an already failing right ventricle. The right-to-left shunt at PDA acts as a pop
off against high right ventricular afterload, and increases shear stress on the pulmonary arterial
endothelium. In addition, the vasopressor effect of commonly used inotropic agents is not selective to
systemic vasculature and may increase the pulmonary arterial pressure as well [9].
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6.9. Sedation/Paralysis
In PPHN, episodes of pulmonary vasoconstriction can be induced by external stimuli. Hence,
these infants should be nursed in an environment with minimal stimulation and provided adequate
sedation with fentanyl/morphine. The routine use of paralyzing agents should be avoided [4] and
reserved for infants who need high ventilator settings to maintain oxygenation and ventilation in the
target range.
6.10. Nutrition
The goal is to provide adequate parenteral calories and maintaining adequate ionic calcium levels
for optimal cardiac function by providing a parenteral nutrition solution with glucose, calcium, amino
acids and lipids.
6.11. Acid–Base Balance
Acidosis promotes pulmonary vasoconstriction and hence it is important to maintain pH in the
normal range (7.25–7.4). Metabolic alkalosis by sodium bicarbonate infusion and respiratory alkalosis
by hyperventilation should be avoided [4] as it has been shown to increase the risk of developmental
delay and sensorineural deafness [44]. PaCO2 should be maintained between 40 and 55 mm Hg.
6.12. Extracorporeal Membrane Oxygenation (ECMO)
About 30–40% of infants do not achieve a sustained oxygenation response to iNO. ECMO may
be lifesaving in infants who fail maximal conventional therapy. Hence, access to ECMO or ability to
transfer patients in a timely manner to an ECMO center should be available to centers that manage
patients with HRF/PPHN. The indications for ECMO are OI >40 for >2 h in 3 out of 5 arterial blood
gases or A-aDO2 ≥ 630 for >4 h. Hypoxemia to this degree is predictive of 60–80% mortality in the
absence of access to ECMO. The risk of rapid deterioration and death is high in patients with severe
PPHN and HRF and hence discussions and initiation of transfer should be undertaken in patients at
an OI of 30 on pulmonary vasodilator therapy. Contraindications to ECMO include gestational age
<34 weeks (due to high risk of intraventricular hemorrhage (IVH)), significant IVH, persistent bleeding
diathesis, irreversible neurological injury, major chromosomal abnormalities and irreversible major
organ dysfunction.
7. Follow-Up
Follow-up studies comparing therapies for PPHN demonstrate that neurodevelopmental
impairments are present in about 25% of infants, sensorineural hearing loss in 6–23% and persisting
respiratory illness in 25%. It is important to ensure long-term multidisciplinary follow up care
following discharge for these infants.
8. Conclusions
Survival of infants with PPHN has significantly improved with the use of gentle ventilation,
surfactant and iNO. However, due to the limited availability of iNO, high cost, and lack of efficacy
in about a third of patients with PPHN, there is a need to develop better agents that target different
enzymatic pathways in the vascular smooth muscle. Newer agents such as L-Citrulline, endothelin
receptor antagonists, soluble guanylyl cyclase stimulators and activators, Rho kinase inhibitors,
peroxisome proliferator activated receptor gamma (PPAR 7) agonists, and antioxidants are in different
stages of development and testing [45]. Further research using these newer agents is likely to reduce
morbidity and mortality associated with PPHN.
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